INSERM, UMR 957, 1 Rue Gaston Veil, 44035 Nantes, France.
Cancers (Basel). 2013 May 24;5(2):591-616. doi: 10.3390/cancers5020591.
Osteosarcoma is the most frequent malignant primary bone tumor and a main cause of cancer-related death in children and adolescents. Although long-term survival in localized osteosarcoma has improved to about 60% during the 1960s and 1970s, long-term survival in both localized and metastatic osteosarcoma has stagnated in the past several decades. Thus, current conventional therapy consists of multi-agent chemotherapy, surgery and radiation, which is not fully adequate for osteosarcoma treatment. Innovative drugs and approaches are needed to further improve outcome in osteosarcoma patients. This review describes the current management of osteosarcoma as well as potential new therapies.
骨肉瘤是最常见的恶性原发性骨肿瘤,也是儿童和青少年癌症相关死亡的主要原因。尽管在 20 世纪 60 年代和 70 年代,局限性骨肉瘤的长期生存率提高到了约 60%,但在过去几十年中,局限性和转移性骨肉瘤的长期生存率都停滞不前。因此,目前的常规治疗包括多药化疗、手术和放疗,但这对于骨肉瘤的治疗并不完全足够。需要创新药物和方法来进一步提高骨肉瘤患者的治疗效果。本文描述了骨肉瘤的当前治疗方法以及潜在的新疗法。